Trending stocks today
Sarepta Therapeutics (SRPT-Q)
NASDAQ:SRPT
119.43
0.60
(0.50%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 1 opinions in the last 12 months.
Experts are concerned about the performance of RNA-based therapeutic companies, such as Sarepta Therapeutics, following a troubling trend possibly linked to the Moderna report. The company's stock may be facing challenges in the current market due to broader industry concerns.
$119.430
Unknown
- «
- ‹
- 1
- ›
- »
Sarepta Therapeutics(SRPT-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 1
Sarepta Therapeutics(SRPT-Q) Frequently Asked Questions
What is Sarepta Therapeutics stock symbol?
Sarepta Therapeutics is a American stock, trading under the symbol SRPT-Q on the NASDAQ (SRPT). It is usually referred to as NASDAQ:SRPT or SRPT-Q
Is Sarepta Therapeutics a buy or a sell?
In the last year, 1 stock analyst published opinions about SRPT-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sarepta Therapeutics.
Is Sarepta Therapeutics a good investment or a top pick?
Sarepta Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Sarepta Therapeutics.
Why is Sarepta Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Sarepta Therapeutics worth watching?
In the last year 1 stock analyst on Stockchase covered Sarepta Therapeutics. The stock is worth watching.
What is Sarepta Therapeutics stock price?
On 2025-01-15, Sarepta Therapeutics (SRPT-Q) stock closed at a price of $119.43.
The RNA-based therapeutic companies are not doing well. Maybe it's a reverse-halo effect of the Moderna report. It's troubling.